Edition:
United Kingdom

Achaogen Inc (AKAO.OQ)

AKAO.OQ on NASDAQ Stock Exchange Global Market

11.37USD
23 Jan 2018
Change (% chg)

$-0.17 (-1.47%)
Prev Close
$11.54
Open
$11.58
Day's High
$11.58
Day's Low
$11.30
Volume
226,586
Avg. Vol
273,213
52-wk High
$27.78
52-wk Low
$10.24

Chart for

About

Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the... (more)

Overall

Beta: 1.53
Market Cap(Mil.): $644.48
Shares Outstanding(Mil.): 42.23
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 85.70 16.62
EPS (TTM): -- -- --
ROI: -- 3.19 10.61
ROE: -- 4.52 14.21

BRIEF-Achaogen Announces Positive Top-Line Results From First Clinical Trial Of Orally-Administered Antibacterial Candidate C-Scape

* ACHAOGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM FIRST CLINICAL TRIAL OF ORALLY-ADMINISTERED ANTIBACTERIAL CANDIDATE C-SCAPE

02 Jan 2018

BRIEF-Achaogen Announces FDA Acceptance Of New Drug Application With Priority Review For Plazomicin

* ACHAOGEN ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION WITH PRIORITY REVIEW FOR PLAZOMICIN FOR TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND BLOODSTREAM INFECTIONS

02 Jan 2018

BRIEF-Achaogen Appoints Blake Wise Chief Executive Officer

* ACHAOGEN INC - KENNETH HILLAN TO BECOME PRESIDENT, RESEARCH AND DEVELOPMENT

11 Dec 2017

BRIEF-Achaogen reports Q3 loss per share $0.85

* Achaogen reports third quarter 2017 financial results and provides corporate update

08 Nov 2017

BRIEF-Achaogen submits Plazomicin new drug application to FDA

* Achaogen submits Plazomicin new drug application (NDA) to the U.S. FDA for treatment of complicated urinary tract infections and bloodstream infections

26 Oct 2017

BRIEF-Achaogen awarded up to $18 million contract by BARDA

* Achaogen awarded up to $18 million contract by BARDA to support development of orally-administered antibacterial candidate C-Scape

28 Sep 2017

BRIEF-Achaogen reports Q2 loss per share $0.78

* Achaogen reports second quarter 2017 financial results and provides corporate update

03 Aug 2017

BRIEF-Point72 Asset Management reports 5.5 pct passive stake in Achaogen

* Point72 Asset Management Lp reports 5.5 percent passive stake in Achaogen Inc as of july 25 - sec filing Source text - http://bit.ly/2vK96pV Further company coverage:

26 Jul 2017

Earnings vs. Estimates